BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang C, Wang R, Zhou K, Wang S, Wang J, Shi H, Dou Y, Yang D, Chang L, Shi X, Liu Y, Xu X, Zhang X, Ke Y, Liu H. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo. Cancer Chemother Pharmacol 2016;78:971-82. [PMID: 27620208 DOI: 10.1007/s00280-016-3149-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Zhu L, Feng X, Zhang H, Luo Q, Chen F. Oridonin induces G2/M cell cycle arrest and apoptosis in human oral squamous cell carcinoma. European Journal of Pharmacology 2017;815:282-9. [DOI: 10.1016/j.ejphar.2017.09.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang C, Yang D, Jiang L, Wang S, Wang J, Zhou K, Shi X, Chang L, Liu Y, Ke Y, Liu H. Jesridonin in combination with paclitaxel demonstrates synergistic anti-tumor activity in human esophageal carcinoma cells. Bioorganic & Medicinal Chemistry Letters 2017;27:2058-62. [DOI: 10.1016/j.bmcl.2017.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Yang H, Khan AR, Liu M, Fu M, Ji J, Chi L, Zhai G. Stimuli-responsive polymeric micelles for the delivery of paclitaxel. Journal of Drug Delivery Science and Technology 2020;56:101523. [DOI: 10.1016/j.jddst.2020.101523] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
4 Shuang W, Hou L, Zhu Y, Li Q, Hu W. Mcl-1 stabilization confers resistance to taxol in human gastric cancer. Oncotarget 2017;8:82981-90. [PMID: 29137317 DOI: 10.18632/oncotarget.20222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ren X, Zhao B, Chang H, Xiao M, Wu Y, Liu Y. Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells. Mol Med Rep. 2018;17:8289-8299. [PMID: 29658576 DOI: 10.3892/mmr.2018.8868] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
6 Riestra-Ayora J, Sánchez-Rodríguez C, Palao-Suay R, Yanes-Díaz J, Martín-Hita A, Aguilar MR, Sanz-Fernández R. Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma: in vivo murine model. Drug Deliv 2021;28:1376-88. [PMID: 34180747 DOI: 10.1080/10717544.2021.1923863] [Reference Citation Analysis]
7 Guo S, Zhang Y, Wu Z, Zhang L, He D, Li X, Wang Z. Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin. Biomed Pharmacother 2019;118:109225. [PMID: 31325705 DOI: 10.1016/j.biopha.2019.109225] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
8 Wang M, Chen L, Huang W, Jin M, Wang Q, Gao Z, Jin Z. Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes. Int J Nanomedicine 2019;14:1385-400. [PMID: 30863067 DOI: 10.2147/IJN.S195375] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]